Dicot AB receives approximately 10 MSEK through the warrants of series TO 3 with a 90% subscription rate
Press release: Uppsala, June 17, 2022.
Dicot AB (publ) ("Dicot" or the "Company") announces the outcome regarding exercising of warrants of series TO 3. Holders of warrants exercised 34,202,814 warrants, corresponding to approximately 90 percent of the number of outstanding warrants, for subscription of 34,202,814 shares at a subscription price of SEK 0.29 per share. Through the exercise of the warrants, Dicot will receive approximately SEK 10 million before issue costs.
Background
During the fourth quarter of 2021, Dicot conducted a rights issue of units, with one (1) unit consisting of three (3) new issued shares and three (3) free-of-charge warrants of series TO 3. Each warrant of series TO 3 entitled the holder to subscribe for one (1) new share in Dicot during the subscription period between June 1 and 15, 2022.
Used warrants have been replaced by interim shares (IS) awaiting registration at the Swedish Companies Registration Office, the conversion of IS into shares is expected to take place during week 27, 2022.
Complete terms of the warrants of series TO 3 is available at Dicot's homepage www.dicot.se
Number of shares and share capital
Through the exercising of the warrants the number of shares of Dicot is increased with 34,202,814 shares, from 102,900,206 to 137,103,020 shares. The share capital is increased by 4,275,352 SEK, from 12,862,526 SEK to 17,137,878 SEK.
For the existing shareholders that did not exercise any warrants of series TO 3 the dilution amounts to approximately 25 percent.
"- It is very gratifying that so many have chosen to exercise their options and show their trust in the company. With this capital injection, we continue our goal-oriented work to develop a new modern potency drug, where the next big milestone is to begin the first studies in humans next year", says Elin Trampe, CEO of Dicot.
Advisers
Stockholm Corporate Finance AB acted as the financial adviser and Advokatfirman Lindahl KB as legal adviser regarding subscription of warrants of series TO 3. Hagberg & Aneborn Fondkommission AB acted as issuing agent regarding the warrants of series TO 3.
For questions regarding the warrants, please contact:
Hagberg & Aneborn Fondkommission AB
Phone: + 46 (0) 840 89 33 50
Email: [email protected]
For additional questions regarding the warrants, please contact:
Elin Trampe, CEO
Phone: +46 (0) 739 80 14 08
Email: [email protected]
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se
This information is such information that Dicot AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation (MAR). The information was submitted, through the agency of the above contact person, for publication on June 17, 2022.
Om Dicot
Dicot utvecklar ett modernt potensläkemedel som ska behandla erektionssvikt och för tidig utlösning bättre än befintliga preparat.
Handelsinformation
IR-Kontakt
